PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

作者
Sagar Lonial,Hang Quach,Meletios Athanasios Dimopoulos,Paula Rodríguez‐Otero,Jesús G. Berdeja,Paul Gerard Guy Richardson,Margee J. Kyada,Shuyu Chu,Min Chen,Patricia C. Abad,Juliane Morando,Niels W.C.J. van de Donk
出处
期刊:HemaSphere [Wolters Kluwer]
卷期号:7 (S3): e3132426-e3132426
标识
DOI:10.1097/01.hs9.0000975292.31324.26
摘要

Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: New treatments (Txs) are needed to achieve deep and durable responses in relapsed/refractory multiple myeloma (RRMM). Iberdomide (IBER) is a novel, potent oral cereblon E3 ligase modulator (CELMoD™) with enhanced tumoricidal and immune-stimulatory effects compared with immunomodulatory drugs (IMiDs®). IBER has synergy with dexamethasone (DEX), daratumumab (DARA), and bortezomib (BORT) in vitro. In a phase 1/2 trial, IBER plus DARA and DEX (IberDd) demonstrated efficacy with a manageable safety profile in patients (pts) with RRMM (Lonial S, et al. HemaSphere 2021;5(S2):S187). Aims: The EXCALIBER-RRMM phase 3 trial (NCT04975997) will compare the efficacy and safety of IberDd with that of DARA plus BORT and DEX (DVd) in pts with early RRMM. Methods: This multicenter, open-label study will be conducted in 2 stages: in Stage 1, ≥ 200 pts will be randomized 1:1:1:1 to 1 of 3 IBER doses (1.0, 1.3, or 1.6 mg) + DARA and DEX or to the DVd arm to identify optimal IBER dose when combined with DARA + DEX; in Stage 2, ≈ 664 additional pts will be randomized 1:1 to IberDd at the selected IBER dose or to DVd, for efficacy and safety analyses (Stage 1 pts in IBER selected dose cohort and DVd arm to be also included). Pts will be stratified by number of prior Tx lines (1 vs 2), age (≤ 70 vs > 70 years), and ISS stage at study entry (I–II vs III). Primary efficacy endpoint is progression-free survival (PFS), which is defined as the time from randomization to progressive disease (PD) or death. Assuming a decrease in PFS risk by 25% (HR = 0.75) with IberDd, under exponential distribution assumption of PFS (1-sided α = 0.025) and adjusted for 3 interim analyses, 458 PFS events will have ≈ 84% power to detect an improvement in Tx effect. The 3 planned interim analyses are: for IBER dose selection at end of Stage 1; and to examine PFS futility and superiority when ≈ 138 (30%) and ≈ 344 (75%) events, respectively, have been accumulated. Secondary endpoints include overall survival, duration of response, time to progression, overall response rate, measurable residual disease negativity rate, safety, and quality of life. Tx in the IberDd arm will consist of 28-day (D) cycles (C) with IBER on D1–21; 1800 mg subcutaneous (SC) DARA on D1, 8, 15, and 22 of C1–2, D1 and 15 of C3–6, and D1 of ≥ C7; and 40 mg oral DEX (20 mg in pts > 75 years of age) on D1, 8, 15, and 22. Tx in the DVd arm will consist of 21-D cycles for C1–8 and 28-D cycles for ≥ C9; 1800 mg SC DARA on D1, 8, and 15 for C1–3, D1 for ≥ C4; 1.3 mg/m² SC BORT on D1, 4, 8, and 11 for C1–8; and 20 mg oral DEX (10 mg in pts > 75 years of age) on D1, 2, 4, 5, 8, 9, 11, and 12 for C1–8. Tx will continue until confirmed PD, unacceptable toxicity, or consent withdrawal. Key eligibility criteria include age ≥ 18 years, 1–2 prior lines of antimyeloma Tx, partial response or better to ≥ 1 prior Tx, and documented PD during or after the last regimen. Prior anti-CD38 Tx is allowed only in Stage 2 (≤ 10% of pts). Results: Enrollment began in June 2022 and is currently ongoing. Summary/Conclusion: This phase 3 study will provide valuable insight into the efficacy and safety of IberDd as a potential treatment for patients with RRMM. © 2023 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2023 ASCO Annual Meeting. All rights reserved. Keywords: Multiple myeloma, Clinical trial, Immunomodulation

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
1秒前
枫叶人生完成签到,获得积分10
2秒前
molihuakai的应助被小巧秋天采纳,获得10
3秒前
3秒前
蓝天发布了新的文献求助10
3秒前
科研通AI2S的应助被TAO采纳,获得10
3秒前
4秒前
zx完成签到,获得积分20
4秒前
LingYi发布了新的文献求助10
4秒前
5秒前
保守派帮主完成签到,获得积分10
5秒前
AK完成签到,获得积分10
5秒前
老妖怪完成签到,获得积分10
6秒前
6秒前
8秒前
9秒前
Jasper的应助被温白开采纳,获得10
9秒前
英俊的铭的应助被linlianhao采纳,获得10
9秒前
小马甲的应助被小懿采纳,获得10
10秒前
10秒前
9465426发布了新的文献求助30
10秒前
iceanbecky发布了新的文献求助10
11秒前
打打的应助被风清扬采纳,获得10
11秒前
任性玫瑰发布了新的文献求助10
11秒前
hmhu完成签到,获得积分10
12秒前
12秒前
欧耶完成签到,获得积分20
12秒前
12秒前
回望发布了新的文献求助10
12秒前
xiaofeixia完成签到 ,获得积分10
13秒前
answer答案完成签到,获得积分10
13秒前
稳稳完成签到,获得积分10
14秒前
56455完成签到,获得积分10
15秒前
iNk的应助被Fantaro采纳,获得10
15秒前
LJH发布了新的文献求助10
15秒前
Qiao发布了新的文献求助10
15秒前
keibinn完成签到 ,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067